Laboratory analysis of positive rate of *Mycoplasma pneumoniae* antibody among 53,273 children with respiratory tract infections in Xi’an from 2017 to 2020

Gai-Li Meng¹, Ru Kang¹, Xiao-Yue Cheng¹, Qi Wang², Yun Xie¹^*

¹Department of Clinical Laboratory, Northwest Women’s and Children’s Hospital, Xi’an, China; ²Department of Clinical Laboratory, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

**Contributions:** (I) Conception and design: GL Meng; (II) Administrative support: R Kang; (III) Provision of study materials or patients: G Meng, XY Cheng; (IV) Collection and assembly of data: Q Wang, Y Xie; (V) Data analysis and interpretation: GL Meng, Y Xie; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Yun Xie. Department of Clinical Laboratory, Northwest Women’s and Children’s Hospital, No. 1616 Yanxiang Road, Xi’an 710061, China. Email: xieyunhero@sina.com.

**Background:** *Mycoplasma pneumoniae* (*Mp*) is an important pathogen that causes respiratory tract infections in children. Data on epidemiology of paediatric *Mp* infection in China are little known. The aim of this study was to investigate the infection of children with respiratory tract infection in Xi’an from 2017 to 2020, and to explore the epidemiological features of paediatric *Mp* infection in Northwest China during the past 4 years.

**Methods:** A total of 53,273 paediatric patients diagnosed with respiratory tract infection as the first diagnosis were enrolled. *Mp* antibody was detected using passive agglutination method. Statistical analysis and epidemiological investigation were carried out on the test results according to different years, seasons, ages and genders. The differences among rates were analyzed by the $\chi^2$ test. The trends among the rates were analyzed by the Poisson regression.

**Results:** A total of 14,375 *Mp* antibody positive patients were detected, with a total positive rate of 26.98%. The rate of *Mp* infection in 2017 was significantly higher than other years ($\chi^2=431.700; P=0.000$), and the rate showed a downward trend year by year [incidence rate ratios (IRR) =0.906; 95% CI: 0.892–0.921; $P=0.000$]. The rate of *Mp* infection increased gradually in the order of spring, summer, autumn and winter (IRR =1.078; 95% CI: 1.060–1.097; $P=0.000$), and peaked in winter (29.08%). As age increased, the positive rate of *Mp* infection also gradually increased (IRR =1.138; 95% CI: 1.134–1.143; $P=0.000$). The peak age of *Mp* infection was between 6 and 12 years, accounting for 51.71%, significantly more compared with other age groups ($\chi^2=4203.000, P=0.000$). Female children had significantly higher positive rates than male children ($\chi^2=527.000; P=0.000$).

**Conclusions:** *Mp* infection mainly occurs related to year, season, age and gender. Understanding the epidemiological characteristics of paediatric *Mp* infection can contribute to timely treatment and diagnosis, and may improve the prognosis of children with *Mp* infection.

**Keywords:** *Mycoplasma pneumoniae* (*Mp*); antibody titer; child

Submitted Feb 24, 2022. Accepted for publication Apr 28, 2022.
doi: 10.21037/tp-22-127

View this article at: https://dx.doi.org/10.21037/tp-22-127

^ ORCID: 0000-0003-4734-4428.
**Introduction**

*Mycoplasma pneumoniae* (*Mp*) is a common pathogenic microorganism that can cause respiratory tract infections in children (1). Additionally, *Mp* is a major cause of community-acquired pneumonia (CAP) in children, and accounts for 10–30% of the pediatric population (2). *Mp* can cause respiratory diseases such as acute and chronic respiratory infections, bronchitis and asthma (3,4). It can also cause extrapulmonary diseases including encephalitis, nephritis, myocarditis and other complications in severe cases (5,6). *Mp* epidemic is cyclical, with an epidemic peak every 3–7 years, and each epidemic lasts for 1–2 years (7). The prevalence of infection is related to season, age, gender, geography and other factors (8,9). However, there have been few studies with large numbers of paediatric patients with *Mp* infection to explore the epidemiology and dynamic characteristics in Northwest China.

In order to find out the epidemic situation of *Mp* infection in Xi’an, to provide the basis for clinical diagnosis, treatment, corresponding prevention and control strategies for children in the local region, we retrospectively analyzed the antibody titers to *Mp* in 53,273 children with respiratory tract infection as the first diagnosis from the Respiratory Medicine Clinic from 2017 to 2020 and a comprehensive statistical analysis was conducted in accordance with the different years, seasons, ages, and genders. We present the following article in accordance with the STROBE reporting checklist (available at https://tp.amegroups.com/article/view/10.21037/tp-22-127/rc).

**Methods**

**Sample collection**

The Northwest Women’s and Children’s Hospital is a women and children specialist hospital located in Xi’an, China. We retrospectively analyzed the antibody titer results of *Mp* in 53,273 paediatric patients (24,459 girls and 28,814 boys) with respiratory tract infection as the first diagnosis, aged from 1 month to 12 years old, who had visited in the Respiratory Medicine Clinic from January 2017 to December 2020. Paediatric patients were all living in Xi’an city. All patients were independent, data of the same individual child during the research period only inclusion of the first visit. This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was reviewed and approved by the Ethics Committee of the Northwest Women’s and Children’s Hospital (No. 21–16).

**Detection of *Mp* antibody titers**

Peripheral blood samples (80 μL) were collected from children and kept at room temperature for at least 20 min. The serum was collected by centrifugation at 3,000 rpm for 10 min. The *Mp* antibody titer detection was performed using an *Mp* antibody detection kit (passive agglutination method; Fuji Ruibai Co., Ltd., Japan). All the operations were performed strictly in accordance with the manufacturer’s instructions. *Mp* infection is defined as single titres of serum *Mp* antibody ≥1:160 measured by the particle agglutination test (10).

**Statistical methods**

The data analysis was conducted with the statistical software SPSS 18.0 (IBM Corp., Chicago, IL, USA). The enumeration data were expressed as the number of cases. The differences among rates were analyzed by the χ² test. The trends among the rates were analyzed by the Poisson regression. A two-sided P value <0.05 was considered statistically significant.

**Results**

**Distribution of *Mp* infection positive rates in different years**

The positive rate of *Mp* infection in children had the highest positive rate in 2017 (37.27%) and the lowest rate in 2019 (24.13%), and the difference between the different years was statistically significant (χ² = 431.700; P=0.000) (Table 1). Additionally, the positive rate of the *Mp* infection in the children tended to decrease over consecutive years (IRR =0.906; 95% CI: 0.892–0.921; P=0.000) (Table 2).

**Distribution of *Mp* infection positive rates in different seasons**

The children had the highest positive *Mp* infection rate in
winter (29.08%) and the lowest in spring (23.34%), and the difference between the different seasons was significant ($\chi^2=129.400; P=0.000$) (Table 3). Further, the positive rate of $Mp$ infection in children tended to gradually increase in the order of spring, summer, autumn, and winter (IRR =1.078; 95% CI: 1.060–1.097; P=0.000) (Table 2).

**Distribution of $Mp$ infection positive rates by gender**

The positive rate of $Mp$ infection in girls (31.78%) was significantly higher than that in boys (22.92%), and there was a significant difference between the genders ($\chi^2=527.000; P=0.000$) (Table 5).

**Discussion**

The $Mp$ pathogen is common in the population, especially in children. Studies have shown that there are significant differences in the positive rate of $Mp$ infection in different countries and regions, populations, years, and seasons.
The prevalence of *Mp* infection varies widely from 8.7–37.5% in different countries worldwide (9,12-14). Gao et al. (9) found that the *Mp* infection rate was 37.5% in children with respiratory symptoms in northern China. Conversely, Jiang et al. (12) found that the *Mp* infection rate was only 12.2% in children with respiratory symptoms in southern China. The results of this study showed that the *Mp* infection rate in children with respiratory symptoms in Xi’an from 2015 to 2020 was 26.98%, which falls somewhere between the 2 above-mentioned rates. Eun et al. (15) found that the epidemic peaks were separated by 3–4 years for *Mp* in Korea. Our study showed that the *Mp* infection rate in children in the Xi’an region was the highest in 2017 (37.27%), decreased in 2018 and 2019 (25.82% and 24.13%), but increased again in 2020 (28.40%). Due to the global epidemic situation of the coronavirus disease of 2019 (COVID-2019) in early 2020, the use of masks and disinfectants or other factors may have reduced the *Mp* infection rate in children in the region in 2020. It appears that the *Mp* epidemic in Xi’an tends to peak every 3–4 years.

Infection with *Mp* occurs in children year-round; however, there are differences across the seasons. A study from northern China found that the *Mp* infection rate was the highest in autumn (9); a study from southern China (Zhejiang) and another from Australia found that the *Mp* infection rate was the highest in summer (July) (12,16); a study in Korea found that the *Mp* infection rate was the highest in autumn or winter (15); and a study from the United States found that the *Mp* infection rate was the highest from August to November (17). The results of our study showed that the *Mp* infection rate in children in the Xi’an area were 23.34%, 25.35%, 28.01%, and 29.08% for spring, summer, autumn, and winter, respectively, and that the trend showed a significant increase. Notably, the highest *Mp* infection rate was in winter (29.08%), followed by autumn. Thus, the prevention and control of *Mp* infection in autumn and winter should be strengthened in Xi’an, especially in winters in endemic years. As the annual infection rate of *Mp* is >20%, the prevention and control of *Mp* in spring and summer should also be emphasized.

There are gender differences in the prevalence of *Mp* infection (9,12). Gao et al. (9), Jiang et al. (12), and Kung et al. (18) showed that the prevalence of *Mp* infection is higher in women than men, which suggested that women may be more susceptible to MP than men. Similarly, we found that there was gender difference in the prevalence of *Mp* infection in our study, the morbidity rate of girls (31.78%) was significantly higher than that of boys (22.92%).

Children may be infected with *Mp* at any age, especially in preschool and school-age children (19). In Japan, the highest incidence of *Mp* infection was among the 7–10 age group (20), while in Australia, it was 5–9 years old (16). The results of the present study had revealed that the infection rates of *Mp* in the infant group, toddler group, preschool, and school-age groups were 5.95%, 21.75%, 29.76%, and

### Table 4 Distribution of positive rates of *Mp* infection in different age groups

| Age (years) | Cases (n) | Positive cases (n) | Positive rate (%) | $\chi^2$ | P value |
|-------------|-----------|--------------------|-------------------|---------|---------|
| 0–1         | 7,513     | 447                | 5.95              |         |         |
| 1–3         | 15,608    | 3,394              | 21.75             |         |         |
| 3–6         | 23,038    | 6,855              | 29.76             |         |         |
| 6–12        | 7,114     | 3,679              | 51.71             |         |         |
| Total       | 53,273    | 14,375             | 26.98             | 4,203.000 | 0.000   |

*Mp*, Mycoplasma pneumoniae.

### Table 5 Distribution of positive rates of *Mp* infection in different genders

| Gender | Cases (n) | Positive cases (n) | Positive rate (%) | $\chi^2$ | P value |
|--------|-----------|--------------------|-------------------|---------|---------|
| Male   | 28,814    | 6,603              | 22.92             |         |         |
| Female | 24,459    | 7,772              | 31.78             |         |         |
| Total  | 53,273    | 14,375             | 26.98             | 527.000 | 0.000   |

*Mp*, Mycoplasma pneumoniae.
51.71%, respectively. The infection rate of Mp in children showed a significantly increasing trend with age. School-age children aged 6–12 years old were more likely to experience Mp infection, which is consistent with most studies (9,16,19,20). However, the Mp infection rate in the infant group (0–1 year old) was the lowest, being only 5.95%, which may be related to the simple living environment and dietary structure (mainly breast milk) of children in that age group. One study has shown that breast milk contains a variety of immunomodulatory and antibacterial substances, which can significantly reduce the risk of respiratory tract infection in children. Breastfeeding is a protective factor for respiratory tract infection (21). Thus, the prevention and control of Mp infection in preschool and school-age children, especially school-age children, should be strengthened in Xi’an. This study was a single center retrospective study, which had some limitations: the included samples had a certain selection bias.

Based on our retrospective analysis, this study revealed that Mp infection in children in Xi’an from 2017 to 2020 was characterized by a high infection rate throughout the year, especially in autumn and winter. The prevalence of Mp infection was significantly higher in girls than in boys. The infection rate of Mp in children increased significantly with age, especially in school-age (6–12 years) children. Thus, effective prevention and control measures should be implemented in autumn and winter to reduce the prevalence ofMp infection among school-age children.

Acknowledgments
Funding: None.

Footnote
Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://tp.amegroups.com/article/view/10.21037/tp-22-127/rc

Data Sharing Statement: Available at https://tp.amegroups.com/article/view/10.21037/tp-22-127/dss

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-22-127/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was reviewed and approved by the Ethics Committee of the Northwest Women’s and Children’s Hospital (No. 21–16). Individual consent for this retrospective study was waived.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
1. Jin X, Zou Y, Zhai J, et al. Refractory Mycoplasma pneumoniae pneumonia with concomitant acute cerebral infarction in a child: A case report and literature review. Medicine (Baltimore) 2018;97:e0103.
2. McCulloh RJ, Patel K. Recent Developments in Pediatric Community-Acquired Pneumonia. Curr Infect Dis Rep 2016;18:14.
3. Meyer Sauteur PM, Unger WW, Nadal D, et al. Infection with and Carriage of Mycoplasma pneumoniae in Children. Front Microbiol 2016;7:329.
4. Zhang Y, Zhou Y, Li S, et al. The Clinical Characteristics and Predictors of Refractory Mycoplasma pneumoniae Pneumonia in Children. PLoS One 2016;11:e0156465.
5. Jujaray D, Juan LZ, Shrestha S, et al. Pattern and Significance of Asymptomatic Elevation of Liver Enzymes in Mycoplasma Pneumonia in Children. Clin Pediatr (Phila) 2018;57:57-61.
6. Waites KB, Xiao L, Liu Y, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev 2017;30:747-809.
7. Carrim M, Wolter N, Benitez AJ, et al. Epidemiology and Molecular Identification and Characterization of Mycoplasma pneumoniae, South Africa, 2012-2015. Emerg Infect Dis 2018;24:506-13.
8. Chang CH, Tsai CK, Tsai TA, et al. Epidemiology and clinical manifestations of children with macrolide-resistant Mycoplasma pneumoniae pneumonia in Southern Taiwan.
9. Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016. Epidemiol Infect 2019;147:e192.
10. Laboratory Medicine Branch of Chinese Pediatric Society of Chinese Medicine Association. Chinese Expert consensus on laboratory diagnosis of respiratory tract infections caused by Mycoplasma pneumoniae in children. Chinese Journal of Laboratory Medicine 2019;42:507-13.
11. Du D, Liao S, Wu Y, et al. Serological Analysis and Drug Resistance of Chlamydia pneumoniae and Mycoplasma pneumoniae in 4500 Healthy Subjects in Shenzhen, China. Biomed Res Int 2017;2017:3120138.
12. Jiang Q, Yang F, Peng Y, et al. Epidemiology and molecular identification of mycoplasma pneumoniae associated with respiratory infections in Zhejiang province, China, 2008-2017. J Clin Lab Anal 2020;34:e23460.
13. Sorensen CM, Schonning K, Rosenfeldt V. Clinical characteristics of children with Mycoplasma pneumoniae infection hospitalized during the Danish 2010-2012 epidemic. Dan Med J 2013;60:A4632.
14. Dumke R, Schnee C, Pletz MW, et al. Mycoplasma pneumoniae and Chlamydia spp. infection in community-acquired pneumonia, Germany, 2011-2012. Emerg Infect Dis 2015;21:426-34.
15. Eun BW, Kim NH, Choi EH, et al. Mycoplasma pneumoniae in Korean children: the epidemiology of pneumonia over an 18-year period. J Infect 2008;56:326-31.
16. Othman N, Isaacs D, Kesson A. Mycoplasma pneumoniae infections in Australian children. J Paediatr Child Health 2005;41:671-6.
17. Puljiz I, Kuzman I, Dakovic-Rode O, et al. Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia: comparison of clinical, epidemiological characteristics and laboratory profiles. Epidemiol Infect 2006;134:548-55.
18. Kung CM, Wang HL. Seroprevalence of Mycobacterium pneumoniae in healthy adolescents in Taiwan. Jpn J Infect Dis 2007;60:352-4.
19. Nolevaux G, Bessaci-Kabouya K, Villenet N, et al. Epidemiological and clinical study of Mycoplasma pneumoniae respiratory infections in children hospitalized in a pediatric ward between 1999 and 2005 at the Reims University Hospital. Arch Pediatr 2008;15:1630-6.
20. Ito I, Ishida T, Osaka M, et al. Culturally verified Mycoplasma pneumoniae pneumonia in Japan: a long-term observation from 1979-99. Epidemiol Infect 2001;127:365-7.
21. Rouw E, von Gartzen A, Weißenborn A. The importance of breastfeeding for the infant. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2018;61:945-51.

Cite this article as: Meng GL, Kang R, Cheng XY, Wang Q, Xie Y. Laboratory analysis of positive rate of Mycoplasma pneumoniae antibody among 53,273 children with respiratory tract infections in Xi’an from 2017 to 2020. Transl Pediatr 2022;11(5):625-630. doi: 10.21037/tp-22-127